48,849
edits
Difference between revisions of "KRAS mutation"
Jump to navigation
Jump to search
→Colorectal cancer
Jensflorian (talk | contribs) (CRC update) |
|||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 8: | Line 8: | ||
*[[Colorectal carcinoma]] (40%).<ref name=pmid19792050>{{Cite journal | last1 = Monzon | first1 = FA. | last2 = Ogino | first2 = S. | last3 = Hammond | first3 = ME. | last4 = Halling | first4 = KC. | last5 = Bloom | first5 = KJ. | last6 = Nikiforova | first6 = MN. | title = The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. | journal = Arch Pathol Lab Med | volume = 133 | issue = 10 | pages = 1600-6 | month = Oct | year = 2009 | doi = 10.1043/1543-2165-133.10.1600 | PMID = 19792050 }}</ref><ref>{{Cite journal | last1 = Imamura | first1 = Y. | last2 = Lochhead | first2 = P. | last3 = Yamauchi | first3 = M. | last4 = Kuchiba | first4 = A. | last5 = Qian | first5 = ZR. | last6 = Liao | first6 = X. | last7 = Nishihara | first7 = R. | last8 = Jung | first8 = S. | last9 = Wu | first9 = K. | title = Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. | journal = Mol Cancer | volume = 13 | issue = | pages = 135 | month = May | year = 2014 | doi = 10.1186/1476-4598-13-135 | PMID = 24885062 }}</ref> | *[[Colorectal carcinoma]] (40%).<ref name=pmid19792050>{{Cite journal | last1 = Monzon | first1 = FA. | last2 = Ogino | first2 = S. | last3 = Hammond | first3 = ME. | last4 = Halling | first4 = KC. | last5 = Bloom | first5 = KJ. | last6 = Nikiforova | first6 = MN. | title = The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. | journal = Arch Pathol Lab Med | volume = 133 | issue = 10 | pages = 1600-6 | month = Oct | year = 2009 | doi = 10.1043/1543-2165-133.10.1600 | PMID = 19792050 }}</ref><ref>{{Cite journal | last1 = Imamura | first1 = Y. | last2 = Lochhead | first2 = P. | last3 = Yamauchi | first3 = M. | last4 = Kuchiba | first4 = A. | last5 = Qian | first5 = ZR. | last6 = Liao | first6 = X. | last7 = Nishihara | first7 = R. | last8 = Jung | first8 = S. | last9 = Wu | first9 = K. | title = Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. | journal = Mol Cancer | volume = 13 | issue = | pages = 135 | month = May | year = 2014 | doi = 10.1186/1476-4598-13-135 | PMID = 24885062 }}</ref> | ||
*lung adenocarcinomas (approx 30%)<ref>{{Cite journal | last1 = Korpanty | first1 = GJ. | last2 = Graham | first2 = DM. | last3 = Vincent | first3 = MD. | last4 = Leighl | first4 = NB. | title = Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. | journal = Front Oncol | volume = 4 | issue = | pages = 204 | month = | year = 2014 | doi = 10.3389/fonc.2014.00204 | PMID = 25157335 }}</ref> | *lung adenocarcinomas (approx 30%)<ref>{{Cite journal | last1 = Korpanty | first1 = GJ. | last2 = Graham | first2 = DM. | last3 = Vincent | first3 = MD. | last4 = Leighl | first4 = NB. | title = Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. | journal = Front Oncol | volume = 4 | issue = | pages = 204 | month = | year = 2014 | doi = 10.3389/fonc.2014.00204 | PMID = 25157335 }}</ref> | ||
* | *Squamous NSCLC (~5%). | ||
*[[Mucinous ovarian tumours]].<ref name=pmid9118042>{{Cite journal | last1 = Cuatrecasas | first1 = M. | last2 = Villanueva | first2 = A. | last3 = Matias-Guiu | first3 = X. | last4 = Prat | first4 = J. | title = K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. | journal = Cancer | volume = 79 | issue = 8 | pages = 1581-6 | month = Apr | year = 1997 | doi = | PMID = 9118042 }}</ref> | |||
Not seen in the context of: | Not seen in the context of: | ||
| Line 15: | Line 16: | ||
===Implication=== | ===Implication=== | ||
====Colorectal cancer==== | |||
In the context of colorectal carcinoma:<ref name=pmid20956938>{{cite journal |author=Dunn EF, Iida M, Myers RA, ''et al.'' |title=Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab |journal=Oncogene |volume= |issue= |pages= |year=2010 |month=October |pmid=20956938 |doi=10.1038/onc.2010.430 |url=}}</ref><ref name=pmid19001320>{{cite journal |author=Di Nicolantonio F, Martini M, Molinari F, ''et al.'' |title=Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer |journal=J. Clin. Oncol. |volume=26 |issue=35 |pages=5705–12 |year=2008 |month=December |pmid=19001320 |doi=10.1200/JCO.2008.18.0786 |url=}}</ref> | In the context of colorectal carcinoma:<ref name=pmid20956938>{{cite journal |author=Dunn EF, Iida M, Myers RA, ''et al.'' |title=Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab |journal=Oncogene |volume= |issue= |pages= |year=2010 |month=October |pmid=20956938 |doi=10.1038/onc.2010.430 |url=}}</ref><ref name=pmid19001320>{{cite journal |author=Di Nicolantonio F, Martini M, Molinari F, ''et al.'' |title=Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer |journal=J. Clin. Oncol. |volume=26 |issue=35 |pages=5705–12 |year=2008 |month=December |pmid=19001320 |doi=10.1200/JCO.2008.18.0786 |url=}}</ref> | ||
*Patient must have ''wild type'' KRAS to get drugs; KRAS mutation predicts resistance to [[cetuximab]] (Erbitux) and [[panitumumab]] (Vectibix). | *Patient must have ''wild type'' KRAS to get drugs; KRAS mutation predicts resistance to [[cetuximab]] (Erbitux) and [[panitumumab]] (Vectibix). | ||
* The vast majority of activating mutations are found in codon 12/13, 61 and 146.<ref>{{Cite journal | last1 = Imamura | first1 = Y. | last2 = Lochhead | first2 = P. | last3 = Yamauchi | first3 = M. | last4 = Kuchiba | first4 = A. | last5 = Qian | first5 = ZR. | last6 = Liao | first6 = X. | last7 = Nishihara | first7 = R. | last8 = Jung | first8 = S. | last9 = Wu | first9 = K. | title = Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. | journal = Mol Cancer | volume = 13 | issue = | pages = 135 | month = May | year = 2014 | doi = 10.1186/1476-4598-13-135 | PMID = 24885062 }}</ref> | * The vast majority of activating mutations are found in codon 12/13, 61 and 146.<ref>{{Cite journal | last1 = Imamura | first1 = Y. | last2 = Lochhead | first2 = P. | last3 = Yamauchi | first3 = M. | last4 = Kuchiba | first4 = A. | last5 = Qian | first5 = ZR. | last6 = Liao | first6 = X. | last7 = Nishihara | first7 = R. | last8 = Jung | first8 = S. | last9 = Wu | first9 = K. | title = Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. | journal = Mol Cancer | volume = 13 | issue = | pages = 135 | month = May | year = 2014 | doi = 10.1186/1476-4598-13-135 | PMID = 24885062 }}</ref> | ||
* KRAS mutations are usually stable between primary and metastatic tumors. <ref>{{Cite journal | last1 = Petaccia de Macedo | first1 = M. | last2 = Melo | first2 = FM. | last3 = Ribeiro | first3 = HSC. | last4 = Marques | first4 = MC. | last5 = Kagohara | first5 = LT. | last6 = Begnami | first6 = MD. | last7 = Neto | first7 = JC. | last8 = Ribeiro | first8 = JS. | last9 = Soares | first9 = FA. | title = KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care. | journal = Am J Cancer Res | volume = 7 | issue = 9 | pages = 1978-1989 | month = | year = 2017 | doi = | PMID = 28979819 }}</ref> | * KRAS mutations are usually stable between primary and metastatic tumors. <ref>{{Cite journal | last1 = Petaccia de Macedo | first1 = M. | last2 = Melo | first2 = FM. | last3 = Ribeiro | first3 = HSC. | last4 = Marques | first4 = MC. | last5 = Kagohara | first5 = LT. | last6 = Begnami | first6 = MD. | last7 = Neto | first7 = JC. | last8 = Ribeiro | first8 = JS. | last9 = Soares | first9 = FA. | title = KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care. | journal = Am J Cancer Res | volume = 7 | issue = 9 | pages = 1978-1989 | month = | year = 2017 | doi = | PMID = 28979819 }}</ref> | ||
* KRAS mutation predict poor response to FOLFOX treatment.<ref name=pmid25870609>{{Cite journal | last1 = Zocche | first1 = DM. | last2 = Ramirez | first2 = C. | last3 = Fontao | first3 = FM. | last4 = Costa | first4 = LD. | last5 = Redal | first5 = MA. | title = Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. | journal = Front Genet | volume = 6 | issue = | pages = 116 | month = | year = 2015 | doi = 10.3389/fgene.2015.00116 | PMID = 25870609 }}</ref> | |||
====Lung cancer==== | |||
In the context of lung cancer:<ref>{{Cite journal | last1 = Riely | first1 = GJ. | last2 = Kris | first2 = MG. | last3 = Rosenbaum | first3 = D. | last4 = Marks | first4 = J. | last5 = Li | first5 = A. | last6 = Chitale | first6 = DA. | last7 = Nafa | first7 = K. | last8 = Riedel | first8 = ER. | last9 = Hsu | first9 = M. | title = Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. | journal = Clin Cancer Res | volume = 14 | issue = 18 | pages = 5731-4 | month = Sep | year = 2008 | doi = 10.1158/1078-0432.CCR-08-0646 | PMID = 18794081 }}</ref> | In the context of lung cancer:<ref>{{Cite journal | last1 = Riely | first1 = GJ. | last2 = Kris | first2 = MG. | last3 = Rosenbaum | first3 = D. | last4 = Marks | first4 = J. | last5 = Li | first5 = A. | last6 = Chitale | first6 = DA. | last7 = Nafa | first7 = K. | last8 = Riedel | first8 = ER. | last9 = Hsu | first9 = M. | title = Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. | journal = Clin Cancer Res | volume = 14 | issue = 18 | pages = 5731-4 | month = Sep | year = 2008 | doi = 10.1158/1078-0432.CCR-08-0646 | PMID = 18794081 }}</ref> | ||
* Mutations are rare in never-smokers. | * Mutations are rare in never-smokers. | ||
* KRAS G12C is the most common G > T transversion mutation in smokers.<ref>{{Cite journal | last1 = Dogan | first1 = S. | last2 = Shen | first2 = R. | last3 = Ang | first3 = DC. | last4 = Johnson | first4 = ML. | last5 = D'Angelo | first5 = SP. | last6 = Paik | first6 = PK. | last7 = Brzostowski | first7 = EB. | last8 = Riely | first8 = GJ. | last9 = Kris | first9 = MG. | title = Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. | journal = Clin Cancer Res | volume = 18 | issue = 22 | pages = 6169-77 | month = Nov | year = 2012 | doi = 10.1158/1078-0432.CCR-11-3265 | PMID = 23014527 }}</ref> | |||
* Biomarker for MEK inhibitors selumetinib and trametinib. | * Biomarker for MEK inhibitors selumetinib and trametinib. | ||
| Line 39: | Line 45: | ||
*[[Molecular pathology]]. | *[[Molecular pathology]]. | ||
*[[Oncogene]]. | *[[Oncogene]]. | ||
*[[BRAF mutation]]. | |||
==References== | ==References== | ||